Prepared for the Next Pandemic – Utilizing New Production Capacities for Streamlined Vaccine Mfg

This informative webinar will delve into the critical aspects of pandemic preparedness, focusing on vaccine development and production. A blueprint of IDT Biologika’s newest state of the art production facility will be presented. Completed in 2022, the facility serves as one of the backbones for IDT’s vaccine manufacturing operations. Understanding the facility’s design and capabilities is crucial for process development. Attendees will learn about the methodology IDT used to establish a production process potentially capable of producing enough vaccines to ensure a rapid distribution to the population in the event of another pandemic. The successful transfer of this process from development scale to a production scale of 2000 liters will also be explained, and attendees will learn more about IDT’s current capacities for large-scale GMP compliant manufacturing of vaccines and biologics.

We look forward to sharing these exciting insights with you!

Key Learnings:

• Facility Design: Get an inside view into IDT Biologika’s modern GMP compliant production facility and learn more about their current capacities and capabilities for large-scale biologics manufacturing.
• Development Approach: Learn more about IDT’s pandemic preparedness program and how it sets up a generic process design for adenovirus vaccine mass production.
• Smooth Transfer to Production: Attain an internal perspective on the challenges that come with large-scale transfer and how IDT overcame these during tech-transfer into production, as well, as how to incorporate these established learnings in future processes.